Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer

PURPOSE: BRAF mutation occurs in 8–15% of colon cancers (CC), and is associated with poor prognosis in metastatic disease. Compared to wild-type BRAF (BRAFWT) disease, stage II/III CC patients with BRAF mutant (BRAFMT) tumors have shorter overall survival after relapse; however, time-to-relapse is n...

詳細記述

保存先:
書誌詳細
出版年:Oncotarget
主要な著者: Dunne, Philip D., Coleman, Helen G., Bankhead, Peter, Alderdice, Matthew, Gray, Ronan T., McQuaid, Stephen, Bingham, Victoria, Loughrey, Maurice B., James, Jacqueline A., McCorry, Amy M.B., Gilmore, Alan, Holohan, Caitriona, Klingbiel, Dirk, Tejpar, Sabine, Johnston, Patrick G., McArt, Darragh G., Nicolantonio, Federica Di, Longley, Daniel B., Lawler, Mark
フォーマット: Artigo
言語:Inglês
出版事項: Impact Journals LLC 2018
主題:
Research Paper
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5862619/
https://ncbi.nlm.nih.gov/pubmed/29568398
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24481
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料